Theseus Pharmaceuticals Income Statement

Financials in millions IDR. Fiscal year is January - December.

Millions IDR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	1,113,514	1,067,779	921,914	822,286	983,160	568,777
Revenue Growth (YoY)	15.15%	15.82%	12.12%	-16.36%	72.86%	-
Cost of Revenue	836,753	812,422	707,489	612,042	566,115	417,106
Gross Profit	276,761	255,357	214,425	210,244	417,045	151,671
Selling, General & Admin	173,634	166,040	140,880	89,351	85,983	73,095
Other Operating Expenses	1,340	2,395	4,980	1,212	3,719	4,227
Operating Expenses	240,153	231,721	202,867	138,510	119,316	98,717
Operating Income	36,608	23,636	11,557	71,734	297,729	52,954
Interest Expense	-47,610	-45,081	-34,589	-32,615	-39,299	-41,665
Interest & Investment Income	17.02	16.52	81.23	1,117	15.53	8.92
Other Non Operating Income (Expenses)	17,952	19,815	11,464	6,570	3,881	2,174
EBT Excluding Unusual Items	6,966	-1,614	-11,487	46,806	262,327	13,472
Gain (Loss) on Sale of Assets	-	-	-	-6.49	14.44	-
Asset Writedown	7,601	7,601	-	33,095	-75,228	-
Other Unusual Items	3,633	3,633	-	-	-	-
Pretax Income	18,201	9,621	-11,487	79,894	187,113	13,472
Income Tax Expense	9,229	6,958	2,593	14,472	56,565	10,974
Earnings From Continuing Operations	8,972	2,663	-14,080	65,423	130,548	2,498
Minority Interest in Earnings	3,031	2,517	1,249	532.4	-183.91	12,900
Net Income	12,003	5,180	-12,832	65,955	130,364	15,398
Net Income to Common	12,003	5,180	-12,832	65,955	130,364	15,398
Net Income Growth	-	-	-	-49.41%	746.62%	-
Shares Outstanding (Basic)	2,069	2,069	2,069	1,992	359	500
Shares Outstanding (Diluted)	2,069	2,069	2,069	1,992	359	500
Shares Change (YoY)	0.08%	-	3.84%	454.26%	-28.12%	-
EPS (Basic)	5.80	2.50	-6.20	33.11	362.73	30.80
EPS (Diluted)	5.80	2.50	-6.20	33.11	362.73	30.80
EPS Growth	-	-	-	-90.87%	1077.85%	-
Free Cash Flow	-120,425	-70,249	-97,021	-147,436	157,160	88,417
Free Cash Flow Per Share	-58.22	-33.96	-46.90	-74.02	437.30	176.83
Gross Margin	24.86%	23.91%	23.26%	25.57%	42.42%	26.67%
Operating Margin	3.29%	2.21%	1.25%	8.72%	30.28%	9.31%
Profit Margin	1.08%	0.48%	-1.39%	8.02%	13.26%	2.71%
Free Cash Flow Margin	-10.81%	-6.58%	-10.52%	-17.93%	15.98%	15.54%
EBITDA	178,056	161,920	136,727	179,861	367,862	111,332
EBITDA Margin	15.99%	15.16%	14.83%	21.87%	37.42%	19.57%
D&A For EBITDA	141,448	138,284	125,169	108,127	70,133	58,378
EBIT	36,608	23,636	11,557	71,734	297,729	52,954
EBIT Margin	3.29%	2.21%	1.25%	8.72%	30.28%	9.31%
Effective Tax Rate	50.71%	72.32%	-	18.11%	30.23%	81.46%
Advertising Expenses	-	2,697	2,771	1,280	517.38	608.29

Source: S&P Global Market Intelligence. Standard template. Financial Sources.